This is an open-label, multicenter, phase 1 study of BBI608 in combination with FOLFIRI + Bavacizumab. This study population is adult Japanese patients with metastatic colorectal cancers in FOLFIRI + Bevacizumab combination therapy.

Inclusion Criteria:

1. A histologically confirmed advanced unresectable, metastatic or recurrent colorectal carcinoma

2. Evaluable patient by RECISTversion 1.1

3. Stage IV

4. ≥ 20 years of age

5. Life expectancy ≥ 3 months.

6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

7. Patients with following organ function within 14 days before enrollment (on the basis of the most recent data during the period if multiple data are available)

   • Hemoglobin (Hg) ≥ 9.0 g/dL
   • Neutrophil count ≥ 1.5 x 103/μL
   • Platelet count ≥ 10 x 104/μL
   • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × institutional upper limit of normal (ULN) [≤ 5 × ULN in presence of liver metastases ]
   • Total bilirubin ≤ 1.5 × institutional ULN [≤ 2 × ULN in presence of liver metastases ]
   • Creatinine ≤ 1.5 × institutional ULN
   • Proteinuria by dipstick urine analysis ≤ 1+. [ UPCR (Urine Albumin-to-Creatinine Ratio) ≤ 1, or protein volume of 24-hour urine collection ≤ 1 g, in the case of patients with a 2+ urine dipstick reading]

8. For female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 30 days after the last protocol treatment dose or 6 months after Bevacizumab treatment.. For male patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 90 days after the last protocol treatment dose or 6 months after Bevacizumab treatment

9. Females of childbearing potential have a negative urine pregnancy test

10. Patients who have provided written voluntary consent in person to participate in this study after fully receiving and understanding the information about this study, including study

Exclusion Criteria:

1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or hormone therapy, or heart therapy within 21 days of the first dose of BBI608
2. Major surgery within 28 days prior to first dose
3. Have had a brain metastases with a symptom or requiring treatment
4. Have had coinstantaneously active multiple primary cancer
5. Have had a carcinomatous pleural effusion, ascites, or cardiac effusion requiring treatment
6. Crohn's disease, ulcerative colitis, small intestine resection, diarrhea (watery diarrhea), paralysis intestinal, Intestinal obstruction
7. Gastrointestinal perforation, tracheo-oesophageal fistula, fistula
8. Unable or unwilling to swallow BBI608 capsules
9. Uncontrolled inter-current illness (such as Grade 3 active infection, or serious respiratory disease)
10. Uncontrolled hypertension
11. Patients with recent history of hemoptysis of more than 2.5 mL of red blood within 28days before the enrolment
12. Abnormal ECGs which are clinically significant within 28 days before enrolment
13. Patients who are New York Heart Association (NYHA) functional classes III, or IV, or unstable angina
14. Patients newly expressing angina within three months (90 days) before the enrolment
15. Have had myocardial infarction within six months (180 days)before the enrolment
16. Administrating with antiarrhythmic drug
17. Patients who are planning to breast-feeding by whichever 30 days after the last administration of BBI608 or by 6 months after the last administration of Bevacizumab
18. Patients of pregnancy or possibility of pregnancy at current time or possibility of pregnancy within 6 months after the last administration of Bevacizumab
19. Have received other investigational products or not finished the assessment in any clinical study within 28 days before enrollment
20. Known severe hypersensitivity to 5-FU/ levofolinate/ irinotecan/Bevacizumab
21. Administration of atazanavir sulfate
22. Prior treatment with BBI608
23. Ineligible for participation in the study in the opinion of the Investigators